Furthermore, in cohort 1, the SensiScreen® FFPE BRAF qPCR Assays (both simplex and multiplex) identified four mutations not already identified with Cobas®, corresponding to an additional identification of 8% mutated cases at the MM cohort. Here, BRAF is linked to Miyoshi myopathy.